Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …

PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy
for relapsed/refractory FLT3-mutated (FLT3 mut) acute myeloid leukemia (AML) but seldom …

Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options,
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …

Background Several important treatment and supportive care strategies have been
implemented over the past 4 decades in the management of acute myeloid leukemia (AML) …

Dendritic cell (DC) vaccines induce specific immune responses that can selectively
eliminate target cells. In recent years, many studies have been conducted to explore DC …

Therapy resistance represents a major clinical challenge in acute myeloid leukemia (AML).
Here we define a 'MitoScore'signature, which identifies high mitochondrial oxidative …

Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …

FLT3 mutations occur in 20–35% patients with newly diagnosed (ND) acute myeloid
leukemia (AML) and confer a higher risk of relapse and inferior overall survival (OS). Given …

Abstract The N6‐methyladenosine (m6A) demethylase FTO plays an oncogenic role in
acute myeloid leukemia (AML). Despite the promising recent progress for developing some …